Jacobio Pharma, a leading biopharmaceutical company, revealed its financial performance for the year ending December 31, 2025. The company's commercial product Glecirasib was officially approved and included in China's NRDL. Additionally, Jacobio Pharma continues to progress its pan-KRAS and Innovative ADC Pipeline. The company made this announcement on March 10, 2026, with headquarters in Beijing, Shanghai, and Boston. Jacobio Pharma is listed on the Hong Kong Stock Exchange under the ticker symbol 1167. This signifies a significant advancement for the company as it consolidates its presence in the pharmaceutical industry.